Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Learning lessons from Pfizer's $800 million failure.

× No keyword cloud information.

3 in total

1. Safety of anacetrapib in patients with or at high risk for coronary heart disease.

Authors: Christopher P Cannon; Sukrut Shah; Hayes M Dansky; Michael Davidson; Eliot A Brinton; Antonio M Gotto; Michael Stepanavage; Sherry Xueyu Liu; Patrice Gibbons; Tanya B Ashraf; Jennifer Zafarino; Yale Mitchel; Philip Barter
Journal: N Engl J Med Date: 2010-11-17 Impact factor: 91.245

2. Effects of torcetrapib in patients at high risk for coronary events.

Authors: Philip J Barter; Mark Caulfield; Mats Eriksson; Scott M Grundy; John J P Kastelein; Michel Komajda; Jose Lopez-Sendon; Lori Mosca; Jean-Claude Tardif; David D Waters; Charles L Shear; James H Revkin; Kevin A Buhr; Marian R Fisher; Alan R Tall; Bryan Brewer
Journal: N Engl J Med Date: 2007-11-05 Impact factor: 91.245

3. Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone.

Authors: M J Forrest; D Bloomfield; R J Briscoe; P N Brown; A-M Cumiskey; J Ehrhart; J C Hershey; W J Keller; X Ma; H E McPherson; E Messina; L B Peterson; W Sharif-Rodriguez; P K S Siegl; P J Sinclair; C P Sparrow; A S Stevenson; S-Y Sun; C Tsai; H Vargas; M Walker; S H West; V White; R F Woltmann
Journal: Br J Pharmacol Date: 2008-06-09 Impact factor: 8.739

3 in total

6 in total

Learning lessons from Pfizer's $800 million failure.

1. Safety of anacetrapib in patients with or at high risk for coronary heart disease.

2. Effects of torcetrapib in patients at high risk for coronary events.

3. Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone.

1. Medicinal chemistry for 2020.

2. Why Drugs Fail in Late Stages of Development: Case Study Analyses from the Last Decade and Recommendations.

3. Compound signature detection on LINCS L1000 big data.

Review 4. Cholesteryl ester transfer protein inhibitors for dyslipidemia: focus on dalcetrapib.

Review 5. Three-dimensional bio-printing: A new frontier in oncology research.

6. The repeated setbacks of HIV vaccine development laid the groundwork for SARS-CoV-2 vaccines.